National Cancer Institute; Notice of Meeting, 14122 [2019-06996]
Download as PDF
<![CDATA[
14122
Federal Register / Vol. 84, No. 68 / Tuesday, April 9, 2019 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Mark P. Rubert, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–435–
1775, rubertm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–16–
274 and PAR–16–275: Adverse Drug Reaction
Research.
Date: May 1, 2019.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Alexander D. Politis,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3210,
MSC 7808, Bethesda, MD 20892, (301) 435–
1150, politisa@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 4, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–06994 Filed 4–8–19; 8:45 am]
BILLING CODE 4140–01–P
Place: National Institutes of Health,
Building 10, Room 6N106, 10 Center Drive,
Bethesda, MD 20892 (Telephone Conference
Call). Dial: 1–650–479–3207, Access Code:
732 082 860.
Contact Person: Robert Yarchoan, M.D.,
Director, Office of HIV and AIDS Malignancy,
Office of the Director, Chief, HIV and AIDS
Malignancy Branch, Center for Cancer
Research, National Cancer Institute, Building
10, Room 6N106, 10 Center Drive, Bethesda,
MD 20892, 240–496–0328,
Robert.Yarchoan@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/bsa/bsa.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 4, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–06996 Filed 4–8–19; 8:45 am]
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Notice of
Meeting
National Institutes of Health
amozie on DSK9F9SC42PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meeting will be held as a
teleconference only and is open to the
public to dial-in for participation.
Individuals who plan to dial-in to the
meeting and need special assistance or
other reasonable accommodations in
order to do so, should notify the Contact
Person listed below in advance of the
meeting.
Name of Committee: National Cancer
Institute Board of Scientific Advisors; Ad
Hoc Subcommittee on HIV and AIDS
Malignancy.
Date: May 24, 2019.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To discuss recommendations of
the BSA Ad Hoc Working Group on
Immunology of Therapies & Vaccines and
Research Structure.
18:15 Apr 08, 2019
Jkt 247001
Name of Committee: Board of Scientific
Counselors, National Institute of Dental and
Craniofacial Research DEBSC.
Date: June 11, 2019.
Time: 8:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health
Building 31, 8600 Rockville Pike, Bethesda,
MD 20892.
Contact Person: Alicia J. Dombroski, Ph.D.,
Director, Division of Extramural Activities,
National Institute of Dental and Craniofacial
Research, National Institutes of Health,
Bethesda, MD 20892.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcr.nih.gov/about/Council
Committees.asp, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: April 4, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–07005 Filed 4–8–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
constitute a clearly unwarranted
invasion of personal privacy.
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, National Institute of Dental
and Craniofacial Research.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended for the review, discussion,
and evaluation of individual grant
applications conducted by the
NATIONAL INSTITUTE OF DENTAL &
CRANIOFACIAL RESEARCH, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
National Center for Advancing
Translational Sciences; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of
meetings of the National Center for
Advancing Translational Sciences.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\09APN1.SGM
09APN1
]]>Agencies
[Federal Register Volume 84, Number 68 (Tuesday, April 9, 2019)]
[Notices]
[Page 14122]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-06996]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meeting will be held as a teleconference only and is open to
the public to dial-in for participation. Individuals who plan to dial-
in to the meeting and need special assistance or other reasonable
accommodations in order to do so, should notify the Contact Person
listed below in advance of the meeting.
Name of Committee: National Cancer Institute Board of Scientific
Advisors; Ad Hoc Subcommittee on HIV and AIDS Malignancy.
Date: May 24, 2019.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To discuss recommendations of the BSA Ad Hoc Working
Group on Immunology of Therapies & Vaccines and Research Structure.
Place: National Institutes of Health, Building 10, Room 6N106,
10 Center Drive, Bethesda, MD 20892 (Telephone Conference Call).
Dial: 1-650-479-3207, Access Code: 732 082 860.
Contact Person: Robert Yarchoan, M.D., Director, Office of HIV
and AIDS Malignancy, Office of the Director, Chief, HIV and AIDS
Malignancy Branch, Center for Cancer Research, National Cancer
Institute, Building 10, Room 6N106, 10 Center Drive, Bethesda, MD
20892, 240-496-0328, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://deainfo.nci.nih.gov/advisory/bsa/bsa.htm, where an
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: April 4, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-06996 Filed 4-8-19; 8:45 am]
BILLING CODE 4140-01-P
